Time is of essence in clinical development of new therapies, and manufacturing is often a real bottleneck for gene therapy products.  At Yposkesi, we have one of the largest AAV (Adeno-Associated Virus) and lentiviral vector production capacities in Europe. Our growing cGMP facilities, dedicated manpower and expertise allow us to easily  accommodate new projects and meet the timeline and budget for your breaking ground in therapeutic treatments.

Yposkesi is a one-stop-shop with both technical expertise and a long-term commitment to quality.
Our services encompass process development, cGMP  manufacturing of AAV and lentiviral vectors, Fill&Finish, QC, QA and regulatory support. We aim to establish an open and trustworthy relationship with you with the ultimate goal  reducing time-to-market and ensuring an uninterrupted supply of viral vectors.

There is a significant industrial challenge to overcome the manufacturing costs of gene therapy products.
As a leading Contract Development Manufacturing Organization (CDMO), Yposkesi is at the forefront of designing new techniques that improve process robustness and scalability, thereby increasing productivity. We have a highly-skilled and dedicated innovation team focused on your evolving needs and requirements for a committed, sustainable and competitive AAV and lentiviral vector supplier.